

SpliSense - A transformative RNA (ASOs) based company for the treatment of Pulmonary diseases

Gili Hart

Company name- SpliSense * Website *<https://splisens> CEO name- Gili Hart *

Biotech/Pharma *

SESSIONS • Next generation of genetic medicine • Advancements in the space of bio-convergence

o Executive Summary and core Technology SpliSense is a clinical stage company focused on the development of transformative RNA-based treatments for pulmonary diseases. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of unmet Cystic Fibrosis mutations and large pulmonary diseases including Muco- obstructive diseases and IPF. Our innovative approach targets unmet needs in pulmonary diseases. SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations restore or reduce proteins function by its novel pulmonary approach.

o Product Profile/Pipeline SpliSense technology is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation. SpliSense, uses its proprietary algorithms for modulating and optimizing its ASOs properties and splicing activity to target sequences. The benefit of ASO technology, on top of its clinical validity, allows a precise organ targeting approach, with proper lung and cells distribution and safety as demonstrated in the IND enabling studies. Utilizing well established and characterized delivery system will hopefully confirm proper lung delivery and lung function improvement in patients.

o Business Strategy The company is advancing its core programs with the aim to advance them in the clinic and potentially for marketing approval

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans The company's most advanced program, SPL84, which is in a global phase 2 and it is expected that the SPL5AC for muco-obstructive diseases and SPL5B for IPF will advance to clinic in 2024.